U.S. market Closed. Opens in 1 day 5 hours 15 minutes

GRTX | Galera Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueN/AN/AN/AN/AN/A
Cost of Revenue259.00K114.00K778.00K368.00K267.00K
Gross Profit-259.00K-114.00K-778.00K-368.00K-267.00K
Operating Expenses46.95M51.23M73.37M70.55M50.69M
Selling, General & Admin22.84M20.21M20.95M15.71M8.36M
Research & Development24.11M31.01M52.42M54.84M42.33M
Other Operating ExpensesN/A-11.07M-7.17M-3.68M-1.25M
Operating Income-46.95M-51.23M-73.37M-70.55M-50.69M
Other Expenses / Income-12.13M-11.07M-7.17M-3.68M-1.25M
Before Tax Income-59.08M-62.29M-80.53M-74.23M-51.94M
Income Tax ExpensesN/A-70.00K7.19M-16.00K-9.00K
Net Income-59.08M-62.22M-87.73M-74.22M-51.93M
Interest ExpensesN/A11.57M7.19M4.88M3.03M
Basic Shares Outstanding44.55M27.09M25.79M24.87M24.81M
Diluted Shares Outstanding44.55M27.09M25.79M24.87M24.81M
EBITDA-46.69M-50.61M-72.56M-69.01M-50.69M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%
EBIT-59.08M-50.72M-73.34M-69.35M-48.91M
EBIT Margin0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙